Sino-US biotech Connect Biopharma Holdings Ltd (NASDAQ: CNTB), headquartered in San Diego, California, and Taicang, Suzhou, China, announced the completion of a Phase I study for CBP-174, its small-molecule H3 receptor antagonist. The drug is being developed to treat pruritus (itch) associated with allergic and inflammatory skin diseases, including atopic dermatitis (AD).
Study Details
The first-in-human Phase I trial enrolled healthy adults to evaluate CBP-174’s safety, tolerability, and pharmacokinetics (PK) versus placebo. Results showed the drug was safe and well-tolerated at doses up to 16mg, with rapid absorption and no serious adverse events. The data will guide dosing for Phase II trials.
Drug Profile
CBP-174 is a highly selective antagonist of peripherally acting H3 receptors, designed to address pruritus in skin conditions like AD. The Phase I findings support its potential as a non-opioid therapy for chronic itch.
Strategic Outlook
Connect Biopharma plans to advance CBP-174 into Phase II trials, targeting patients with AD and other inflammatory skin diseases. The company aims to leverage its dual US-China presence to accelerate development.-Fineline Info & Tech
